REVIEW article
Front. Allergy
Sec. Therapies and Therapeutic Targets
Volume 6 - 2025 | doi: 10.3389/falgy.2025.1688464
This article is part of the Research TopicClinical and molecular aspects of managing Chronic Urticaria: Identifying endotypes, phenotypes, and factors determining responses and resistance to treatmentView all 4 articles
Predictors of Response to Omalizumab and Relapse in Chronic Spontaneous Urticaria: A Narrative Review Focusing on Parameters Available in Routine Clinical Practice
Provisionally accepted
- Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Institut d’Investigació Biomèdica Sant Pau (IIB SANT PAU), Universitat Autònoma de Barcelona, Barcelona, Spain, Barcelona, Spain
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Chronic spontaneous urticaria (CSU) is a heterogeneous disease with variable responses to treatment. Identifying predictors of response to omalizumab and relapse after its discontinuation is essential for optimizing management. This narrative review aims to summarize current evidence, emphasizing clinically accessible parameters to provide a practical guide for physicians in routine care settings. Response to omalizumab appears to be influenced by the underlying pathophysiological subtype of CSU. Type IIB autoimmune CSU, associated with lower total IgE levels, higher IgG anti-thyroid peroxidase levels, basopenia, eosinopenia, elevated C-reactive protein, and greater disease activity, correlates with poorer responses. Coexisting inducible urticaria is associated with the need for longer duration of omalizumab therapy. Patients with higher body mass index may be poor responders to omalizumab at licensed doses but may benefit from dose escalation. Predictors of relapse after discontinuation include high baseline disease activity, which may be related to type IIB autoimmune CSU, and longer disease duration. Achieving complete disease control prior to tapering omalizumab may also reduce the risk of recurrence. In conclusion, clinically accessible parameters can assist in predicting response to omalizumab and relapse risk. These indicators can support individualized treatment decisions and counseling in daily practice. Further research is needed to refine relapse predictors and validate strategies such as treatment optimization.
Keywords: chronic spontaneous urticaria, Omalizumab, predictor, relapse, response, Recurrence
Received: 19 Aug 2025; Accepted: 29 Sep 2025.
Copyright: © 2025 Mateu-Arrom, Vence-Nogueira, Puig and Spertino. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Laura Mateu-Arrom, lmateuarrom@hotmail.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.